Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference Jan 11, 2024
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds Jan 05, 2024
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea Jan 05, 2024
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol Jan 04, 2024
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Jan 03, 2024
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million Jan 02, 2024
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) Jan 02, 2024
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Dec 29, 2023
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer Dec 18, 2023
